Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

9536 ARTÍCULOS , VIENDO DEL 6481 AL 6495

Leisure activities, apolipoprotein E e4 status, and the risk of dementia

Yang SY, Weng PH, Chen JH, Chiou JM, Lew-Ting CY, Chen TF, Sun Y, Wen LL, Yip PK, Chu YM, Chen YC.

J Formos Med Assoc. 2015 Dec;114(12):1216-24. doi: 10.1016/j.jfma.2014.09.006. Epub 2014 Nov 4.

Biomarkers, ketone bodies, and the prevention of Alzheimer's disease

VanItallie TB.

Metabolism. 2015 Mar;64(3 Suppl 1):S51-7. doi: 10.1016/j.metabol.2014.10.033. Epub 2014 Oct 30.

Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort

Teng E, Chow N, Hwang KS, Thompson PM, Gylys KH, Cole GM, Jack CR Jr, Shaw LM, Trojanowski JQ, Soares HD, Weiner MW, Apostolova LG; Alzheimer’s Disease Neuroimaging Initiative.

Dement Geriatr Cogn Disord. 2015;39(3-4):154-66. doi: 10.1159/000368982. Epub 2014 Dec 24.

Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective

Lewczuk P, Mroczko B, Fagan A, Kornhuber J.

Adv Med Sci. 2015 Mar;60(1):76-82. doi: 10.1016/j.advms.2014.11.002. Epub 2014 Dec 9.

Montreal cognitive assessment: validation study for mild cognitive impairment and Alzheimer disease

Freitas S, Simões MR, Alves L, Santana I.

Alzheimer Dis Assoc Disord. 2013 Jan-Mar;27(1):37-43. doi: 10.1097/WAD.0b013e3182420bfe.

Cerebellar atrophy in patients with subcortical-type vascular cognitive impairment

Yoon CW, Seo SW, Park JS, Kwak KC, Yoon U, Suh MK, Kim GH, Shin JS, Kim CH, Noh Y, Cho H, Kim MJ, Kim JH, Roh JH, Lee JM, Na DL.

Cerebellum. 2013 Feb;12(1):35-42. doi: 10.1007/s12311-012-0388-0.

Patterns of compensation and vulnerability in normal subjects at risk of Alzheimer's disease

Lopez OL, Becker JT, Kuller LH.

J Alzheimers Dis. 2013;33 Suppl 1(0 1):S427-38. doi: 10.3233/JAD-2012-129015.

Recent advances in imaging Alzheimer's disease

Braskie MN, Toga AW, Thompson PM.

J Alzheimers Dis. 2013;33 Suppl 1(0 1):S313-27. doi: 10.3233/JAD-2012-129016.

From genetics to dietetics: the contribution of epidemiology to understanding Alzheimer's disease

Barberger-Gateau P, Lambert JC, Féart C, Pérès K, Ritchie K, Dartigues JF, Alpérovitch A.

J Alzheimers Dis. 2013;33 Suppl 1:S457-63. doi: 10.3233/JAD-2012-129019.

Oxidative modification of brain proteins in Alzheimer's disease: perspective on future studies based on results of redox proteomics studies

Sultana R, Butterfield DA.

J Alzheimers Dis. 2013;33 Suppl 1:S243-51. doi: 10.3233/JAD-2012-129018.

Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention

Caselli RJ, Reiman EM.

J Alzheimers Dis. 2013;33 Suppl 1(0 1):S405-16. doi: 10.3233/JAD-2012-129026.

Degenerative jargon aphasia: unusual progression of logopenic/phonological progressive aphasia?

Caffarra P, Gardini S, Cappa S, Dieci F, Concari L, Barocco F, Ghetti C, Ruffini L, Prati GD.

Behav Neurol. 2013;26(1-2):89-93. doi: 10.3233/BEN-2012-110218.

Spelling intervention in post-stroke aphasia and primary progressive aphasia

Tsapkini K, Hillis AE.

Behav Neurol. 2013;26(1-2):55-66. doi: 10.3233/BEN-2012-110240.

Nonfluent/agrammatic PPA with in-vivo cortical amyloidosis and Pick's disease pathology

Caso F, Gesierich B, Henry M, Sidhu M, LaMarre A, Babiak M, Miller BL, Rabinovici GD, Huang EJ, Magnani G, Filippi M, Comi G, Seeley WW, Gorno-Tempini ML.

Behav Neurol. 2013;26(1-2):95-106. doi: 10.3233/BEN-2012-120255.

Treatment for apraxia of speech in nonfluent variant primary progressive aphasia

Henry ML, Meese MV, Truong S, Babiak MC, Miller BL, Gorno-Tempini ML.

Behav Neurol. 2013;26(1-2):77-88. doi: 10.3233/BEN-2012-120260.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias